Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | XBP1 | P17861 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18077305 | 0.92 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2HPGDMRGPRX4 | |
| SCHEMBL337560 | 0.91 | MRGPRX4 (0.58) | NPC1RAB9ASMN1; SMN2HPGDMRGPRX4 | |
| SCHEMBL177169 | 0.85 | THRA (0.56) | NPC1RAB9ASMN1; SMN2HPGDMRGPRX4 | |
| SCHEMBL4687860 | 0.85 | MRGPRX4 (0.46) | NPC1RAB9ASMN1; SMN2HPGDMRGPRX4 | |
| SCHEMBL566426 | 0.84 | THRA (0.62) | NPC1RAB9ASMN1; SMN2HPGDMRGPRX4 | |
| SCHEMBL566466 | 0.84 | THRA (0.66) | NPC1RAB9ASMN1; SMN2HPGDMRGPRX4 | |
| SCHEMBL13125267 | 0.84 | MRGPRX4 (0.54) | NPC1RAB9ASMN1; SMN2HPGDMRGPRX4 | |
| SCHEMBL9622885 | 0.84 | PLAU (0.62) | NPC1RAB9ASMN1; SMN2HPGDMRGPRX4 | |
| SCHEMBL9623589 | 0.84 | PKM (0.60) | NPC1RAB9ASMN1; SMN2HPGDMRGPRX4 | |
| SCHEMBL28383737 | 0.84 | THRA (0.49) | NPC1RAB9ASMN1; SMN2HPGDMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEWYORK | 2023-12-28 | — | — | US | disclosed |
| EP-4217355-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | Forkhead Biotherapeutics, inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022066938-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FORKHEAD BIOTHERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-6927008-B2 | Photosensitive transfer material | FUJI PHOTO FILM CO., LTD. (JP) | 2005-08-09 | — | — | US | disclosed |
| US-20040106061-A1 | Photosensitive transfer material | FUJI PHOTO FILM CO., LTD. | 2004-06-03 | — | — | US | disclosed |
| WO-2001029014-A1 | ISOTHIAZOLE-5-CARBOXYLIC ESTERS AS MICROBICIDES | NIHON BAYER AGROCHEM K.K. (JP) | 2001-04-26 | — | — | WO | disclosed |
| EP-0056153-B1 | PROCESS FOR PRODUCING COMPOUNDS HAVING S-TRIAZINE UNITS AND EPOXY GROUPS, AND THEIR USES AS INCORPORABLE FILLING MATERIALS IN THE PRODUCTION OF POLYURETHANE PLASTIC MATERIALS | BAYER AG (DE) | 1985-12-04 | — | — | EP | disclosed |
| US-4384102-A | Process for the preparation of compounds having s-triazine units and epoxide groups | BAYER AKTIENGESELLSCHAFT (DE) | 1983-05-17 | — | — | US | disclosed |
| EP-0056153-A2 | Process for producing compounds having s-triazine units and epoxy groups, and their uses as incorporable filling materials in the production of polyurethane plastic materials | BAYER AG (DE) | 1982-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FOXO1, FOXO3, GCKR | NPC1 1891/4885RAB9A 1754/4885SMN1; SMN2 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.